FluoroPharma's cardiac PET tracer shows promise

02/10/2014 | MolecularImaging.net

FluoroPharma Medical presented preliminary results from a Phase II clinical trial of its F-18 FCPHA cardiac PET agent last week. "F-18 FCPHA was well-tolerated and administered safely in study subjects at [the University of Louvain], part of a multicenter study in Belgium. F-18 FCPHA demonstrated rapid blood clearance with excellent image quality and image time was optimal, as early as three minutes post- injection," said researcher Dr. Fabian Demeure.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Director, Payer Marketing
Avalere Health
Washington, DC
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX